Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levornidazole and Sodium Chloride Injection PK and Safety in Normal vs Impaired Hepatic Function
CTR20260361Phase 4Active
- Sponsor
- Shijiazhuang No. 4 Pharmaceutical
- Start
- Feb 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of levornidazole in amebiasis, hepatic amoebiasis and surgical site infection (SSI) (2 cohorts), sponsored by Shijiazhuang No. 4 Pharmaceutical. Primary endpoints: Pharmacokinetic parameters of levornidazole, Pharmacokinetic parameters of active metabolites M1, M2, M4 and 1 more. Started Feb 2026; status: active.
02
Drugs
levornidazole
03
Conditions
amebiasishepatic amoebiasissurgical site infection (SSI)
Beyond the preview
Go deeper on CTR20260361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260361.